【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 2719次   下载 2233 本文二维码信息
码上扫一扫!
吉西他滨联合顺铂方案与氟尿嘧啶联合顺铂方案治疗晚期鼻咽癌疗效和不良反应的Meta分析
衷敬华1,2,刘瑞林3,陈晶4,胡喜钢5,王黎青2,王勇2*
0
(1.赣南医学院第一附属医院急诊科,赣州 341000;2.南方医科大学珠江医院药剂科,广州 510282; 3.南方医科大学珠江医院,广州 510282;4.南方医科大学珠江医院信息科,广州 510282;5.南方医科大学珠江医院肿瘤中心,广州 510282)
摘要:
目的:比较吉西他滨联合顺铂方案与氟尿嘧啶联合顺铂方案治疗晚期鼻咽癌的疗效与不良反应的差异。方法:采用Cochrane系统评价方法,检索Cochrane图书馆临床对照试验库、MEDLINE、EMBASE、CBM、CNKI等数据库,并辅以手工检索和附加检索。检索时间截至2008年。由2名评价者独立评价并交叉核对纳入研究质量,对同质研究采用RevMan 5.0软件进行分析。结果:共纳入4个研究,283例晚期鼻咽癌患者,分析结果表明,GP方案(吉西他滨+顺铂)与FP方案(氟尿嘧啶+顺铂)的1年、3年生存率相似(Z=0.89,P=0.37)、(Z=1.70,P=0.09),但具有更高的总缓解率(Z=2.34,P=0.02),具有相对低的致骨髓毒性和消化道反应(Z=2.47,P=0.01)、(Z=3.20,P=0.001)、(Z=2.19,P=0.03)。结论:吉西他滨联合顺铂方案与氟尿嘧啶联合顺铂方案相比,具有相当的疗效和更轻微的不良反应。
关键词:  鼻咽肿瘤  吉西他滨  氟尿嘧啶  顺铂  Meta分析
DOI:10.3724/SP.J.1008.2009.0926
投稿时间:2009-02-04修订日期:2009-07-12
基金项目:广东省科技计划项目(2008B030301157),广东省自然科学基金(07005203),国家自然科学基金(30471928).
Efficacy and adverse effects of gemcitabine plus cisplatin regimen and fluorouracil plus cisplatin regimen in treatment of advanced nasopharyngeal carcinoma:a meta-analysis
ZHONG Jing-hua1,2,LIU Rui-lin3 ,CHEN Jing4,HU Xi-gang5,WANG Li-qing2 ,WANG Yong2*
(1.Department of Emergency,First Affiliated Hospital of Gannan Medical University,Ganzhou 341000,China;2.Department of Pharmacy,Zhujiang Hospital,Southern Medical University,Guangzhou 510282;3.Zhujiang Hospital,Southern Medical University,Guangzhou 510282; 4.Department of Information,Zhujiang Hospital,Southern Medical University,Guangzhou 510282;5.Department of Oncology,Zhujiang Hospital,Southern Medical University,Guangzhou 510282)
Abstract:
Objective:To compare the efficacy and adverse reactions between gemcitabine+cisplatin regimen and fluorouracil+cisplatin regimen in the treatment of advanced nasopharyngeal carcinoma (NPC).Methods:The Cochrane Library,MEDLINE,EMbase,CBM and CNKI were searched for related articles published before 2009.Manual searching and additional searching were also performed.The quality of each included studies was evaluated by 2 independent oncologists and analyses of homogeneous property of the studies were done by RevMan 5.0 software.Results:Four studies were enrolled in our study,including 283 patients with NPC.Meta-analyses showed that the 1-year- and 3-year-survival rates of gemcitabine+cisplatin regimen were similar to those of fluorouracil+cisplatin regimen (Z=0.89,P=0.37),(Z=1.70,P=0.09),but gemcitabine+cisplatin regimen had significantly higher remission rate (Z=2.34,P=0.02) and slighter myelosuppression and gastrointestinal reactions (Z=2.47,P=0.01),(Z=3.20,P=0.001),(Z=2.19,P=0.03).Conclusion:Gemcitabine+cisplatin regimen has equivalent efficacy and slighter adverse effects compared with fluorouracil+cisplatin regimen in treatment of advanced nasopharyngeal carcinoma.
Key words:  nasopharyngeal neoplasms  gemcitabine  fluorouracil  cisplatin  Meta-analyses